AAV-mediated gene transfer for retinal diseases.

Area of Science:

• Ophthalmology
• Gene Therapy
• Molecular Biology

Background:

• Adeno-associated virus (AAV) vectors are effective for long-term gene transduction in the retina of various animal models.
• AAV serotypes can target specific retinal cells like photoreceptors and retinal pigment epithelium, crucial for treating blinding diseases.
• Gene therapy using AAV has demonstrated proof-of-principle for both dominant and recessive retinal disorders in preclinical models.

Purpose of the Study:

• To evaluate the efficacy and safety of AAV-mediated gene transfer for retinal diseases.
• To explore gene therapy as an alternative to gene replacement for inherited and complex retinal traits.
• To assess the potential of AAV gene therapy for treating human inherited retinal diseases.

Main Methods:

• Utilizing various AAV serotypes for gene transfer to retinal cells in animal models.
• Achieving constitutive and regulated gene expression at therapeutic levels in the retina.
• Investigating gene transfer of neurotrophic or antiangiogenic molecules.

Main Results:

• Successful long-term transduction of retinal cells in animal models, including non-human primates.
• Restoration of vision in dogs with congenital blindness through AAV-mediated gene therapy.
• Demonstrated efficacy and safety in preclinical models of inherited retinal disorders.

Conclusions:

• AAV vectors offer a versatile and safe platform for retinal gene therapy.
• Gene transfer of therapeutic molecules presents an alternative treatment strategy for retinal diseases.
• The immune privilege of the retina and AAV's versatility may lead to the first successful human gene therapy for inherited diseases.